FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1667-1675 December 6, 2001 Number 23 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.

Methods A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.

Results Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure: 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting–enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.

Conclusions Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.

Source Information

From the Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (J.N.C.); and the Mario Negri Institute, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, Milan, Italy (G.T.).

Address reprint requests to Dr. Cohn at the Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St., SE, Minneapolis, MN 55455.

Full Text of this Article

This article has been cited by other articles:

• Authors/Task Force Members, , Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Tendera, M., Auricchio, A., Bax, J., Bohm, M., Corra, U., della Bella, P., Elliott, P. M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.-L., Verheugt, F. W. A., Zamorano, J. L., Zannad, F. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442 [Full Text]  
• Franks, A. M, O'Brien, C. E, Stowe, C. D, Wells, T. G, Gardner, S. F (2008). Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children. The Annals of Pharmacotherapy 42: 1388-1395 [Abstract] [Full Text]  
• Masson, S., Latini, R., Anand, I. S., Barlera, S., Angelici, L., Vago, T., Tognoni, G., Cohn, J. N., for the Val-HeFT Investigators, (2008). Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52: 997-1003 [Abstract] [Full Text]  
• Crespo, M. J., Cruz, N., Altieri, P. I., Escobales, N. (2008). Enalapril and Losartan Are More Effective Than Carvedilol in Preventing Dilated Cardiomyopathy in the Syrian Cardiomyopathic Hamster. J CARDIOVASC PHARMACOL THER 13: 199-206 [Abstract]  
• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Therapeutic Advances in Cardiovascular Disease 2: 233-248 [Abstract]  
• Henz, S., Maeder, M. T., Huber, S., Schmid, M., Loher, M., Fehr, T. (2008). Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 0: gfn380v1-gfn380 [Abstract] [Full Text]  
• Ootaki, C., Yamashita, M., Ootaki, Y., Kamohara, K., Weber, S., Klatte, R. S., Smith, W. A., Massiello, A. L., Emancipator, S. N., Golding, L. A.R., Fukamachi, K. (2008). Reduced Pulsatility Induces Periarteritis in Kidney: Role of the Local Renin-Angiotensin System. J. Thorac. Cardiovasc. Surg. 136: 150-158 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• de Denus, S., Zakrzewski-Jakubiak, M., Dube, M.-P., Belanger, F., Lepage, S., Leblanc, M.-H., Gossard, D., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Touyz, R. M, Turgeon, J., White, M. (2008). Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. The Annals of Pharmacotherapy 42: 925-932 [Abstract] [Full Text]  
• Werner, C. M., Bohm, M. (2008). Review: The therapeutic role of RAS blockade in chronic heart failure. Therapeutic Advances in Cardiovascular Disease 2: 167-177 [Abstract]  
• Kasama, S., Toyama, T., Sumino, H., Nakazawa, M., Matsumoto, N., Sato, Y., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M. (2008). Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. JNM 49: 907-914 [Abstract] [Full Text]  
• MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., McMurray, J. J.V. (2008). Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29: 1224-1240 [Abstract] [Full Text]  
• McMurray, J. J.V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., Lewsey, J., for the Aliskiren Observation of Heart Failure Tre, (2008). Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circ Heart Fail 1: 17-24 [Abstract] [Full Text]  
• Anand, I. S., Rector, T. S., Kuskowski, M., Thomas, S., Holwerda, N.J., Cohn, J. N. (2008). Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 1: 34-42 [Abstract] [Full Text]  
• Verjans, J. W.H., Lovhaug, D., Narula, N., Petrov, A. D., Indrevoll, B., Bjurgert, E., Krasieva, T. B., Petersen, L. B., Kindberg, G. M., Solbakken, M., Cuthbertson, A., Vannan, M. A., Reutelingsperger, C. P.M., Tromberg, B. J., Hofstra, L., Narula, J. (2008). Noninvasive Imaging of Angiotensin Receptors After Myocardial Infarction. J Am Coll Cardiol Img 1: 354-362 [Abstract] [Full Text]  
• McMurray, J. J.V. (2008). ACE Inhibitors in Cardiovascular Disease -- Unbeatable?. NEJM 358: 1615-1616 [Full Text]  
• The ONTARGET Investigators, (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 358: 1547-1559 [Abstract] [Full Text]  
• Coffman, T. M., Crowley, S. D. (2008). Kidney in Hypertension: Guyton Redux. Hypertension 51: 811-816 [Full Text]  
• Bourge, R. C., Abraham, W. T., Adamson, P. B., Aaron, M. F., Aranda, J. M. Jr, Magalski, A., Zile, M. R., Smith, A. L., Smart, F. W., O'Shaughnessy, M. A., Jessup, M. L., Sparks, B., Naftel, D. L., Stevenson, L. W., on behalf of the COMPASS-HF Study Group, (2008). Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.. J Am Coll Cardiol 51: 1073-1079 [Abstract] [Full Text]  
• Agirbasli, M., Cincin, A., Baykan, O. A (2008). Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors. Journal of Renin-Angiotensin-Aldosterone System 9: 22-26 [Abstract]  
• Gradman, A. H., Kad, R. (2008). Renin inhibition in hypertension.. J Am Coll Cardiol 51: 519-528 [Abstract] [Full Text]  
• Choudhary, R., Palm-Leis, A., Scott, R. C. III, Guleria, R. S., Rachut, E., Baker, K. M., Pan, J. (2008). All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 294: H633-H644 [Abstract] [Full Text]  
• Goldstein, N. E., Fischberg, D. (2008). Update in Palliative Medicine. ANN INTERN MED 148: 135-140 [Full Text]  
• Yagi, S., Aihara, K.-i., Ikeda, Y., Sumitomo, Y., Yoshida, S., Ise, T., Iwase, T., Ishikawa, K., Azuma, H., Akaike, M., Matsumoto, T. (2008). Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency. Circ. Res. 102: 68-76 [Abstract] [Full Text]  
• Triller, D. M., Hamilton, R. A. (2007). Effect of pharmaceutical care services on outcomes for home care patients with heart failure. Am J Health Syst Pharm 64: 2244-2249 [Abstract] [Full Text]  
• Parikh, N. I., Gona, P., Larson, M. G., Wang, T. J., Newton-Cheh, C., Levy, D., Benjamin, E. J., Kannel, W. B., Vasan, R. S. (2007). Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28: 2644-2652 [Abstract] [Full Text]  
• Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., Krumholz, H. M. (2007). Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. Arch Intern Med 167: 1930-1936 [Abstract] [Full Text]  
• Latini, R., Masson, S., Anand, I. S., Missov, E., Carlson, M., Vago, T., Angelici, L., Barlera, S., Parrinello, G., Maggioni, A. P., Tognoni, G., Cohn, J. N., for the Val-HeFT Investigators, (2007). Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. Circulation 116: 1242-1249 [Abstract] [Full Text]  
• Duckelmann, C., Mittermayer, F., Haider, D. G., Altenberger, J., Eichinger, J., Wolzt, M. (2007). Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure. Arterioscler. Thromb. Vasc. Bio. 27: 2037-2042 [Abstract] [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 50: e28-e55 [Full Text]  
• Mozaffarian, D., Anker, S. D., Anand, I., Linker, D. T., Sullivan, M. D., Cleland, J. G.F., Carson, P. E., Maggioni, A. P., Mann, D. L., Pitt, B., Poole-Wilson, P. A., Levy, W. C. (2007). Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model. Circulation 116: 392-398 [Abstract] [Full Text]  
• Marciante, K. D., Bis, J. C., Rieder, M. J., Reiner, A. P., Lumley, T., Monks, S. A., Kooperberg, C., Carlson, C., Heckbert, S. R., Psaty, B. M. (2007). Renin-Angiotensin System Haplotypes and the Risk of Myocardial Infarction and Stroke in Pharmacologically Treated Hypertensive Patients. Am J Epidemiol 166: 19-27 [Abstract] [Full Text]  
• Hennekens, C. H., Pfeffer, M. A., Swedberg, K. (2007). The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. J CARDIOVASC PHARMACOL THER 12: 124-126 [Abstract]  
• Johnson, M. J (2007). Management of end stage cardiac failure. Postgrad. Med. J. 83: 395-401 [Abstract] [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761-2788 [Full Text]  
• Friedrich, E. B, Bohm, M. (2007). MANAGEMENT OF END STAGE HEART FAILURE. Heart 93: 626-631 [Full Text]  
• Taylor, A. L., Ziesche, S., Yancy, C. W., Carson, P., Ferdinand, K., Taylor, M., Adams, K., Olukotun, A. Y., Ofili, E., Tam, S. W., Sabolinski, M. L., Worcel, M., Cohn, J. N., on behalf of the African-American Heart Failure Tr, (2007). Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial. Circulation 115: 1747-1753 [Abstract] [Full Text]  
• Neubauer, S. (2007). The Failing Heart -- An Engine Out of Fuel. NEJM 356: 1140-1151 [Full Text]  
• Allen, L. A., O'Connor, C. M. (2007). Management of acute decompensated heart failure. CMAJ 176: 797-805 [Abstract] [Full Text]  
• LeFebvre, J., Shintani, A., Gebretsadik, T., Petro, J. R., Murphey, L. J., Brown, N. J. (2007). Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade. J. Pharmacol. Exp. Ther. 320: 1261-1267 [Abstract] [Full Text]  
• Anand, I. S., Tam, S. W., Rector, T. S., Taylor, A. L., Sabolinski, M. L., Archambault, W. T., Adams, K. F., Olukotun, A. Y., Worcel, M., Cohn, J. N. (2007). Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49: 32-39 [Abstract] [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Struthers, A D (2006). Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart 92: 1728-1731 [Abstract] [Full Text]  
• Skali, H., Pfeffer, M. A., Lubsen, J., Solomon, S. D. (2006). Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials. Circulation 114: 2298-2303 [Abstract] [Full Text]  
• Edwards, N.C., Steeds, R.P., Ferro, C.J., Townend, J.N. (2006). The treatment of coronary artery disease in patients with chronic kidney disease. QJM 99: 723-736 [Abstract] [Full Text]  
• Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., Bonow, R. O. (2006). Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation 114: 1202-1213 [Full Text]  
• Kirby, M. (2006). Heart failure and diabetes in primary care. British Journal of Diabetes & Vascular Disease 6: 220-228 [Abstract]  
• Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R., Dohi, Y. (2006). Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant 21: 2507-2512 [Abstract] [Full Text]  
• Groban, L., Butterworth, J. (2006). Perioperative management of chronic heart failure.. Anesth. Analg. 103: 557-575 [Abstract] [Full Text]  
• Howard, P. A, Cheng, J. W., Crouch, M. A, Colucci, V. J, Kalus, J. S, Spinler, S. A, Munger, M. (2006). Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. The Annals of Pharmacotherapy 40: 1607-1616 [Abstract] [Full Text]  
• Julius, S., Weber, M. A., Kjeldsen, S. E., McInnes, G. T., Zanchetti, A., Brunner, H. R., Laragh, J., Schork, M. A., Hua, T. A., Amerena, J., Balazovjech, I., Cassel, G., Herczeg, B., Koylan, N., Magometschnigg, D., Majahalme, S., Martinez, F., Oigman, W., Seabra Gomes, R., Zhu, J.-r. (2006). The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy. Hypertension 48: 385-391 [Abstract] [Full Text]  
• Strauss, M. H., Hall, A. S. (2006). Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox. Circulation 114: 838-854 [Full Text]  
• Tsuyuki, R. T., McDonald, M. A. (2006). Response to Tsuyuki and McDonald. Circulation 114: 855-860 [Full Text]  
• (2006). ACE inhibitor-ARB Combination therapy May Be indicated forNephropathy. DOC News 3: 5-5 [Full Text]  
• McMurray, J., Swedberg, K. (2006). Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J 27: 1773-1777 [Abstract] [Full Text]  
• Masson, S., Latini, R., Anand, I. S., Vago, T., Angelici, L., Barlera, S., Missov, E. D., Clerico, A., Tognoni, G., Cohn, J. N., on behalf of the Val-HeFT Investigators, (2006). Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data. Clin. Chem. 52: 1528-1538 [Abstract] [Full Text]  
• Meredith, P. A, Ostergren, J. (2006). Review: From Hypertension to Heart Failure -- Are There Better Primary Prevention Strategies?. Journal of Renin-Angiotensin-Aldosterone System 7: 64-73 [Abstract]  
• Hennekens, C. H., Kowalczykowski, M., Hollar, D. (2006). Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and {beta}-Blockers in the Treatment of Patients With Heart Failure. J CARDIOVASC PHARMACOL THER 11: 149-152 [Abstract]  
• Lechat, P. (2006). The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Eur Heart J Suppl 8: C5-C12 [Abstract] [Full Text]  
• Gheorghiade, M., van Veldhuisen, D. J., Colucci, W. S. (2006). Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation 113: 2556-2564 [Full Text]  
• Kasama, S, Toyama, T, Hatori, T, Sumino, H, Kumakura, H, Takayama, Y, Ichikawa, S, Suzuki, T, Kurabayashi, M (2006). Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 92: 625-630 [Abstract] [Full Text]  
• Cleland, J. G.F., Charlesworth, A., Lubsen, J., Swedberg, K., Remme, W. J., Erhardt, L., Di Lenarda, A., Komajda, M., Metra, M., Torp-Pedersen, C., Poole-Wilson, P. A., for the COMET Investigators, (2006). A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure: A Report From the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 47: 1603-1611 [Abstract] [Full Text]  
• Brady, A J B, Poole-Wilson, P A (2006). ESC-CHF: guidelines for the aspirational and the practical.. Heart 92: 437-440 [Abstract] [Full Text]  
• Volpe, M., Tocci, G., Pagannone, E. (2006). Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.. J. Am. Soc. Nephrol. 17: S36-S43 [Abstract] [Full Text]  
• Levy, W. C., Mozaffarian, D., Linker, D. T., Sutradhar, S. C., Anker, S. D., Cropp, A. B., Anand, I., Maggioni, A., Burton, P., Sullivan, M. D., Pitt, B., Poole-Wilson, P. A., Mann, D. L., Packer, M. (2006). The Seattle Heart Failure Model: Prediction of Survival in Heart Failure. Circulation 113: 1424-1433 [Abstract] [Full Text]  
• Ferrario, C. M (2006). Role of Angiotensin II in Cardiovascular Disease -- Therapeutic Implications of More Than a Century of Research. Journal of Renin-Angiotensin-Aldosterone System 7: 3-14 [Abstract]  
• Tsouli, S. G., Liberopoulos, E. N., Kiortsis, D. N., Mikhailidis, D. P., Elisaf, M. S. (2006). Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. J CARDIOVASC PHARMACOL THER 11: 1-15 [Abstract]  
• Nickenig, G., Ostergren, J., Struijker-Boudier, H. (2006). Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers. Journal of Renin-Angiotensin-Aldosterone System 7: S1-S7 [Abstract]  
• Deedwania, P. C, Schmieder, R. (2006). Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome. Journal of Renin-Angiotensin-Aldosterone System 7: S12-S18 [Abstract]  
• Liu, P. P, Maggioni, A., Velazquez, E. J (2006). Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal of Renin-Angiotensin-Aldosterone System 7: S19-S22 [Abstract]  
• Gilbert, R. E., Connelly, K., Kelly, D. J., Pollock, C. A., Krum, H. (2006). Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. CJASN 1: 193-208 [Abstract] [Full Text]  
• Muller, D. N., Luft, F. C. (2006). Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage. CJASN 1: 221-228 [Abstract] [Full Text]  
• McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., Kober, L., Van de Werf, F., Califf, R., Pfeffer, M. (2006). The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction: An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47: 726-733 [Abstract] [Full Text]  
• Ahmed, A., Rich, M. W., Love, T. E., Lloyd-Jones, D. M., Aban, I. B., Colucci, W. S., Adams, K. F., Gheorghiade, M. (2006). Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27: 178-186 [Abstract] [Full Text]  
• Marcy, T. R., Ripley, T. L. (2006). Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm 63: 49-58 [Abstract] [Full Text]  
• Aranda, J. M. Jr, Woo, G. W., Schofield, R. S., Handberg, E. M., Hill, J. A., Curtis, A. B., Sears, S. F., Goff, J. S., Pauly, D. F., Conti, J. B. (2005). Management of Heart Failure After Cardiac Resynchronization Therapy: Integrating Advanced Heart Failure Treatment With Optimal Device Function. J Am Coll Cardiol 46: 2193-2198 [Abstract] [Full Text]  
• Carson, P., Anand, I., O'Connor, C., Jaski, B., Steinberg, J., Lwin, A., Lindenfeld, J., Ghali, J., Barnet, J. H., Feldman, A. M., Bristow, M. R. (2005). Mode of Death in Advanced Heart Failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. J Am Coll Cardiol 46: 2329-2334 [Abstract] [Full Text]  
• Aronow, W. S. (2005). Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. J. Gerontol. A Biol. Sci. Med. Sci. 60: 1597-1605 [Abstract] [Full Text]  
• White, H. D., Aylward, P. E.G., Huang, Z., Dalby, A. J., Weaver, W. D., Barvik, S., Marin-Neto, J. A., Murin, J., Nordlander, R. O., van Gilst, W. H., Zannad, F., McMurray, J. J.V., Califf, R. M., Pfeffer, M. A., for the VALIANT Investigators, (2005). Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112: 3391-3399 [Abstract] [Full Text]  
• Goldsmith, S. R., Gheorghiade, M. (2005). Vasopressin Antagonism in Heart Failure. J Am Coll Cardiol 46: 1785-1791 [Abstract] [Full Text]  
• Wallis, J., Lygate, C. A., Fischer, A., ten Hove, M., Schneider, J. E., Sebag-Montefiore, L., Dawson, D., Hulbert, K., Zhang, W., Zhang, M. H., Watkins, H., Clarke, K., Neubauer, S. (2005). Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure: Insights From Creatine Transporter-Overexpressing Transgenic Mice. Circulation 112: 3131-3139 [Abstract] [Full Text]  
• Verdecchia, P., Angeli, F., Gattobigio, R., Reboldi, G. P. (2005). Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 26: 2381-2386 [Abstract] [Full Text]  
• van de Wal, R. M.A., van Veldhuisen, D. J., van Gilst, W. H., Voors, A. A. (2005). Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J 26: 2361-2367 [Abstract] [Full Text]  
• Krum, H. (2005). The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J 26: 2472-2472 [Full Text]  
• McDonald, M. A, Simpson, S. H, Ezekowitz, J. A, Gyenes, G., Tsuyuki, R. T (2005). Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331: 873- [Abstract] [Full Text]  
• Tendera, M. (2005). Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Eur Heart J Suppl 7: J5-J9 [Abstract] [Full Text]  
• Reiffel, J. A. (2005). Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. J CARDIOVASC PHARMACOL THER 10: S45-S58 [Abstract]  
• McMurray, J. J.V. (2005). The role of angiotensin II receptor blockers in the management of heart failure. Eur Heart J Suppl 7: J10-J14 [Abstract] [Full Text]  
• Nathan, S., Pepine, C. J., Bakris, G. L. (2005). Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients. Hypertension 46: 637-642 [Abstract] [Full Text]